Tracers / [177Lu]Lu-Evans
[177Lu]Lu-Evans
Also written as [Lu-177]Lu-Evans
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- investigational
- Syntheses indexed
- 0
What it is
- Compound class
- FAP-targeted radiopharmaceutical (Evans blue-modified FAPI conjugate)
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 40049742
- Clinical application
- Recurrent or metastatic solitary fibrous tumor PMID 40049742
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [177Lu]Lu-Evans, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 28: added indication(s) onc-sarcoma from consolidated missing-rubric review.